A detailed history of Jefferies Group LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Jefferies Group LLC holds 9,250 shares of SAGE stock, worth $113,682. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,250
Previous 9,250 -0.0%
Holding current value
$113,682
Previous $298,000 21.48%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Sep 21, 2023

BUY
$27.52 - $37.99 $130,720 - $180,452
4,750 Added 105.56%
9,250 $298,000
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $85,477 - $117,996
3,106 Added 50.55%
9,250 $299,000
Q1 2022

Sep 21, 2023

BUY
$30.71 - $45.71 $61,235 - $91,145
1,994 Added 79.57%
4,500 $148,000
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $111,722 - $166,292
3,638 Added 145.17%
6,144 $148,000
Q4 2021

Sep 21, 2023

SELL
$37.06 - $47.11 $55,367 - $70,382
-1,494 Reduced 37.35%
2,506 $106,000
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $55,367 - $70,382
-1,494 Reduced 37.35%
2,506 $107,000
Q3 2021

Sep 21, 2023

SELL
$40.26 - $57.37 $840,548 - $1.2 Million
-20,878 Reduced 83.92%
4,000 $177,000
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $840,548 - $1.2 Million
-20,878 Reduced 83.92%
4,000 $177,000
Q2 2021

Sep 21, 2023

BUY
$54.88 - $79.29 $322,584 - $466,066
5,878 Added 30.94%
24,878 $1.41 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $322,584 - $466,066
5,878 Added 30.94%
24,878 $1.41 Million
Q1 2021

Sep 21, 2023

BUY
$70.65 - $96.76 $70,650 - $96,760
1,000 Added 5.56%
19,000 $1.42 Million
Q1 2021

May 14, 2021

BUY
$70.65 - $96.76 $70,650 - $96,760
1,000 Added 5.56%
19,000 $1.42 Million
Q4 2020

Sep 21, 2023

BUY
$58.41 - $89.06 $511,087 - $779,275
8,750 Added 94.59%
18,000 $1.56 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $554,895 - $846,070
-9,500 Reduced 34.55%
18,000 $1.56 Million
Q3 2020

Nov 13, 2020

SELL
$41.13 - $62.45 $308,475 - $468,375
-7,500 Reduced 21.43%
27,500 $1.68 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $639,278 - $1.06 Million
24,635 Added 237.67%
35,000 $1.46 Million
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $163,515 - $482,981
-6,253 Reduced 37.63%
10,365 $298,000
Q4 2019

Feb 13, 2020

BUY
$60.18 - $154.77 $204,250 - $525,289
3,394 Added 25.67%
16,618 $1.2 Million
Q3 2019

Nov 13, 2019

BUY
$140.29 - $189.96 $462,255 - $625,918
3,295 Added 33.19%
13,224 $1.86 Million
Q2 2019

Aug 14, 2019

SELL
$157.85 - $183.09 $1.04 Million - $1.2 Million
-6,571 Reduced 39.82%
9,929 $1.82 Million
Q1 2019

May 15, 2019

BUY
$89.33 - $163.65 $808,168 - $1.48 Million
9,047 Added 121.39%
16,500 $2.62 Million
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $610,698 - $1.04 Million
7,453 New
7,453 $714,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $730M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.